Archives

  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • Sitagliptin Phosphate Monohydrate: Potent DPP-4 Inhibitor...

    2026-03-20

    Sitagliptin Phosphate Monohydrate: Potent DPP-4 Inhibitor for Type II Diabetes Research

    Executive Summary: Sitagliptin phosphate monohydrate is a highly selective dipeptidyl peptidase 4 (DPP-4) inhibitor with an IC50 of ~18–19 nM under standard assay conditions (APExBIO). It increases endogenous incretin hormones (GLP-1, GIP), directly supporting glucose homeostasis (Bethea et al., 2025). The compound has demonstrated efficacy in oral animal models, reducing atherosclerotic plaque burden via AMPK and MAPK pathway modulation. It is soluble to ≥23.8 mg/mL in DMSO or ≥30.6 mg/mL in water with sonication, but insoluble in ethanol. APExBIO's reagent provides batch-verified quality and is widely used in metabolic disease research and cell-based incretin studies (compare).

    Biological Rationale

    DPP-4 is a serine protease that regulates the activity of incretin hormones. Incretins such as GLP-1 and GIP stimulate insulin secretion in response to oral glucose. DPP-4 rapidly degrades these peptides, terminating their insulinotropic effects. Inhibiting DPP-4 increases the half-life and circulating levels of GLP-1 and GIP, enhancing insulin secretion and supporting glucose regulation (Bethea et al., 2025). Intestinal stretch and nutrient ingestion both stimulate GLP-1 secretion, contributing to satiety and glucose homeostasis. Pharmacological DPP-4 inhibition is thus a validated strategy for improving glycemic control in type II diabetes mellitus. Sitagliptin phosphate monohydrate is optimized for these research purposes, offering selective, potent, and reproducible inhibition of DPP-4 (APExBIO).

    Mechanism of Action of Sitagliptin phosphate monohydrate

    Sitagliptin phosphate monohydrate (SKU A4036) is the phosphate salt hydrate of sitagliptin, a triazolopyrazine-based compound. It acts as a competitive, reversible inhibitor of DPP-4. The compound binds to the active site of DPP-4, blocking the enzymatic cleavage of peptides bearing N-terminal alanine or proline residues. This results in the preservation of endogenous GLP-1 and GIP, both of which enhance postprandial insulin secretion. Sitagliptin’s selectivity for DPP-4 over related proteases (e.g., DPP-8, DPP-9) is confirmed by in vitro enzyme inhibition assays. The compound’s molecular weight is 523.3 g/mol, and its chemical formula is C16H15F6N5O·H3PO4·H2O. It is highly soluble in DMSO (≥23.8 mg/mL) and water with ultrasonic assistance (≥30.6 mg/mL), but insoluble in ethanol. In vivo, oral administration has demonstrated bioactivity in murine models at 10–50 mg/kg doses, supporting reductions in atherosclerotic plaque via AMPK and MAPK signaling pathways (reviewed).

    Evidence & Benchmarks

    • Sitagliptin phosphate monohydrate inhibits DPP-4 with an IC50 of ~18–19 nM (fluorometric assay, pH 7.5, 25°C) (APExBIO).
    • Oral administration to ApoE−/− mice at 10–50 mg/kg reduces atherosclerotic plaque by up to 40% within 12 weeks (AMPK/MAPK dependent) (Bethea et al., 2025).
    • In cell models, sitagliptin increases SDF-1α ligand expression and promotes differentiation of endothelial progenitor cells (EPCs) and mesenchymal stem cells (MSCs) (see detailed assay).
    • Dissolves to ≥23.8 mg/mL in DMSO and ≥30.6 mg/mL in water (sonication, ambient temperature); not soluble in ethanol (product data).
    • GLP-1 and GIP concentrations increase 1.5–2.5 fold following DPP-4 inhibition in rodent models (ELISA, 2h post oral gavage) (Bethea et al., 2025).
    • Batch-to-batch consistency and purity are independently verified by APExBIO (HPLC >98%) (APExBIO).

    Applications, Limits & Misconceptions

    Sitagliptin phosphate monohydrate is primarily used for:

    • In vitro enzyme inhibition assays targeting DPP-4 (pH 7.5, 25°C, fluorometric or colorimetric readout).
    • Cell-based studies of incretin hormone modulation, especially GLP-1 and GIP stabilization.
    • In vivo metabolic and atherosclerosis models, particularly in genetically modified mice (e.g., ApoE−/− background).
    • Investigations of AMPK and MAPK signaling in the context of metabolic and vascular homeostasis.

    Compared to this prior review focused on DPP-4 selectivity, this article details solution handling, cell-based endpoints, and atherosclerosis outcomes. For actionable protocol guidance, see scenario-driven workflows—this article extends those with new animal model data. For reproducibility and troubleshooting, this guide clarifies batch parameters, but here we summarize peer-reviewed efficacy endpoints and solution chemistry.

    Common Pitfalls or Misconceptions

    • Not effective in DPP-4 knockout models; lacks target engagement without DPP-4 protein.
    • Does not inhibit DPP-8 or DPP-9 at concentrations up to 10 μM—selectivity is high, but not absolute for all serine proteases.
    • Solubility is poor in ethanol; reconstitution in aqueous or DMSO solvents is required for reliable dosing.
    • Long-term storage of dissolved solutions (>24 h) can lead to degradation; prepare fresh aliquots as recommended by APExBIO.
    • Not indicated for studies of nutrient-independent GLP-1 signaling, as its main mechanism relies on endogenous incretin stabilization.

    Workflow Integration & Parameters

    For in vitro assays, dissolve the compound in DMSO (≥23.8 mg/mL) or water with ultrasonic assistance (≥30.6 mg/mL). Use freshly prepared solutions and avoid freeze-thaw cycles. Store powder at −20°C in a desiccated environment. For cell culture, pre-warm solutions to 37°C and filter-sterilize as needed. In animal studies, oral gavage at 10–50 mg/kg is standard for metabolic endpoints. Monitor GLP-1 and GIP via ELISA at 1–4 hours post-dosing. For atherosclerosis studies, employ ApoE−/− mice and quantify plaque area via histology after 8–12 weeks. Always verify batch identity and purity; APExBIO provides HPLC and MS certificates of analysis with each lot. For protocol troubleshooting, see workflow guidance in this applied solutions article.

    Conclusion & Outlook

    Sitagliptin phosphate monohydrate is a reference DPP-4 inhibitor for research on incretin-based therapies, glucose regulation, and atherosclerosis. Its validated selectivity, robust solubility in DMSO and water, and proven in vivo efficacy support its use across metabolic research models. APExBIO ensures batch consistency and comprehensive documentation. Future research may extend its use to multi-target metabolic interventions, but its primary value remains as a precise tool for dissecting DPP-4-dependent incretin biology (Bethea et al., 2025). For product details and ordering, refer to Sitagliptin phosphate monohydrate (SKU A4036).